ArticleSurgery today2026

Impact of thyroid-stimulating hormone ratio change on the progression-free survival of patients receiving gemcitabine, cisplatin, and durvalumab therapy for advanced biliary tract cancer.

Michinori Matsumoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.